World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: PACTR
Last refreshed on: 21 June 2021
Main ID:  PACTR202008871179105
Date of registration: 30/07/2020
Prospective Registration: Yes
Primary sponsor: CDT Africa Addis Ababa University
Public title: Praziquantel therapy for Schistosoma manson infection in preschool-aged children
Scientific title: Optimization of praziquantel therapy for Schistosoma mansoni infection in preschool-aged children in Ethiopia: PrazOpt
Date of first enrolment: 01/09/2020
Target sample size: 218
Recruitment status: Other
URL:  https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12251
Study type:  Interventional
Study design:  Parallel: different groups receive different interventions at same time during study,Non-randomised,Numbered containers  
Phase:  Not Applicable
Countries of recruitment
Ethiopia
Contacts
Name: Eyasu Makonnen    Eshetu
Address:  Zambia street Addis Ababa Ethiopia
Telephone: +251911247556
Email: eyasumakonnen@yahoo.com
Affiliation:  Deputy Head of CDT Africa of Addis Ababa University
Name: Abebaw Fekadu    Wassie
Address:  Zambia street Addis Ababa Ethiopia
Telephone: +251912894975
Email: abebaw.fekadu@aau.edu.et
Affiliation:  Head of CDT Africa of Addis Ababa University
Key inclusion & exclusion criteria
Inclusion criteria: - Written informed consent by parents/guardian
- Age greater than or equal to 48 months and less than or equal to 84 months
- Submission of 2 stool samples at baseline assessment

Exclusion criteria: - Presence of any severe medical problem
- Recent anthelminthic treatment
- Use of other drugs within 5 half-lives of enrolment
- History of hypersensitivity to praziquantel
- Patients with ocular cysticercosis
- Participation in other studies.


Age minimum: 2 Year(s)
Age maximum: 5 Year(s)
Gender: Both
Health Condition(s) or Problem(s) studied

Schistosomiasis
Schistosomiasis
Intervention(s)
Praziquantel
Primary Outcome(s)
cure rate
Secondary Outcome(s)
- Egg reduction rate
- Safety and tolerability (adverse events)
- Estimates of pharmacokinetic parameters (AUC, Cmax, Tmax, t1/2, Tlag)
- Correlates of curative outcome

Secondary ID(s)
Source(s) of Monetary Support
EDCTP
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 08/03/2020
Contact:
info@ethernet.edu.et
info@ethernet.edu.et
+251118721747
info@ethernet.edu.et
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history